Reports that prostate specific antigen (PSA) doubling time seems to be a predictor of the probability of distant metastasis and prostate-cancer specific survival in men with biochemical relapse after r...
The PSA doubling rate calculator is mostly used for assessing the risk of recurrence, or unfavorable outcomes of the treatment. Check your calculated doubling time in months: >6 months is a positive predictor - in the case of an illness, less aggressive treatment is recommended, and survival is...
The PSA Doubling Time Calculator calculates rate of PSA doubling in prostate cancer (correlates with survival).
PSADTMedian metastasis-free survival (year) Proximal PSA<10 ng/mLProximal PSA ≥10 ng/mLP value 6.01-12 mths 20 (n = 277) 5 (n = 64) <.0001 3.01-6 mths 7 (n = 106) 3 (n = 47) 0.0009 < =3 mths 3 (n = 48) 1 (n = 21) 0.058 * Base...
At 3 years, the overall and specific survival rates were 93% and 100% respectively. The estimated 5-year overall survival rate was 87% and specific survival was 96%. bDFS at 3 years was 56.1%. The estimated 5-year bDFS was 41.2% (Figure 1)....
Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients 2007, Annals of Oncology Citation Excerpt : PSA levels present great variability among patients; this is explained by different PSA expression by prostate cancer...
In this study, Inovio evaluated the tolerability and immunogenicity of INO-5150, a DNA vaccine encoding PSA and PSMA, with or without INO-9012 (encoding IL-12 immune adjuvant), in men with biochemically relapsed prostate cancer. The study demonstrated a slowi...
et al. Abiraterone and increased survival in metastatic prostatecancer. N Engl J Med 2011;364:1995 – 2005.7. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, PensonDF, et al. Sipuleucel-T immunotherapy for castration-resistantprostate cancer. N Engl J Med 2010;363:411 – 22.8....
PSA doubling time is not a useful predictive tool for predicting response to docetaxel. By means of overall survival, the clinical stage at the time of diagnosis was the best predictive tool for our cohort. The best PSA response rate to docetaxel chemotherapy was found to be a valuable ...
PSA doubling time (PSADT) and proximal PSA predict metastasis-free survival (MFS) in men with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy (RP): Implications for patient counseling and clinical trial designdoi:10.1093/annonc/mdx370.035M. Markowski...